Glucose 40% Labesfal (Glucose)

Glucose 40% Labesfal is indicated for several clinical situations where rapid carbohydrate delivery is needed.

• Management of acute hypoglycemia in patients who cannot ingest oral glucose, providing an immediate source of carbohydrate.
• Fluid and electrolyte replacement as part of intravenous therapy, helping to maintain volume status while delivering energy.
• Component of total parenteral nutrition formulations, contributing caloric content and preventing catabolism during periods without enteral intake.
• Support during perioperative fasting or prolonged starvation, supplying glucose to sustain cellular metabolism.
• Adjunct in the treatment of hyperosmolar states in diabetic emergencies, helping to lower serum osmolality while correcting glucose deficits.

Intravenous administration of Glucose 40% Labesfal may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Local irritation, erythema, or pain at the infusion site, especially with rapid infusion rates.
• Transient elevation of blood glucose levels (hyperglycemia) that typically resolves with monitoring and adjustment of infusion rate.
• Electrolyte imbalances such as mild hypokalemia, hyponatremia, or shifts in calcium levels due to osmotic effects.
• Nausea, mild abdominal discomfort, or a feeling of fullness during or shortly after infusion.

Serious

• Severe hyperglycemia that may precipitate osmotic diuresis, dehydration, or, in predisposed individuals, diabetic ketoacidosis.
• Allergic reactions ranging from urticaria and pruritus to anaphylactic shock, requiring immediate medical intervention.
• Volume overload leading to pulmonary edema or congestive heart failure in patients with compromised cardiac function.

When using Glucose 40% Labesfal, clinicians should observe several precautions to minimize risks and ensure safe administration.

• Verify patient’s blood glucose level before initiating infusion to avoid exacerbating hyperglycemia.
• Adjust infusion rate according to individual metabolic needs and monitor glucose frequently during therapy.
• Assess fluid status and cardiac function, especially in patients at risk for volume overload or heart failure.
• Use compatible IV sets and avoid mixing with solutions that may precipitate or cause incompatibility.
• Monitor electrolytes, particularly potassium and sodium, as rapid glucose infusion can shift serum concentrations.
• Exercise caution in patients with known glucose intolerance, diabetes mellitus, or metabolic disorders.

Glucose 40% Labesfal can interact with other intravenously administered agents; awareness of these interactions helps prevent complications.

Avoid

• Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring, as this may precipitate severe hypoglycemia.
• Mixing with calcium-containing solutions that can cause precipitation, especially in alkaline pH environments.

Use with caution

• Concurrent use with diuretics (e.g., furosemide) may exacerbate electrolyte shifts; monitor potassium and sodium levels.
• Administration alongside catecholamines (e.g., epinephrine) can increase metabolic demand and raise glucose levels; adjust infusion rates accordingly.
• Use with other hyperosmolar solutions (e.g., mannitol) may increase risk of hyperosmolar syndrome; monitor serum osmolality.